Major Depressive Disorder
Conditions
Brief summary
This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.
Interventions
DRUGCelecoxib
The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
DRUGMinocycline
Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
Sponsors
Stony Brook University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Current consent form signed * Capacity to give informed consent * Age range 18-65 (inclusive) * Diagnosis of MDD or bipolar depression and currently in a major depressive episode * Score of at least 29 on the MADRS (at least moderate depression)
Exclusion criteria
* Hypersensitivity to celecoxib, minocycline, tetracyclines, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs * History of myocardial infarction or current cardiac condition * Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib or minocycline * Poor CYP2C9 metabolizer * Currently taking medications that interact with celecoxib (digoxin, antihypertensives, diuretics, anticoagulant or anti-platelet treatment, including aspirin), or minocycline (isotretinoin, ergot alkaloids) without providing physicians approval * Use of herbs, drugs, or medications with anti-inflammatory or immunomodulatory properties (within 5 half-lives of starting celecoxib or minocycline treatment) * Unlikely to tolerate medication washout or the medication-free period following washout. * Participant considered at significant risk for suicide. * Electroconvulsive therapy (ECT) within 1 month * High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis) * Significant active physical illness or neurological deficit that may affect brain functioning. * If participant is currently pregnant, breastfeeding, or planning to conceive during the course of study participation. * Need for medications that control mania.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Hamilton Depression Rating Scale (HAM-D 24) Score at 8 Weeks | Baseline and 8 weeks. | Participants will have a Hamilton Depression Rating Scale-24 (HDRS) score obtained at baseline. Minimum score 0, maximum possible score 75; the higher the score on the scale, the more severe the degree of depression. After eight weeks of medication treatment, the HDRS score will be reevaluated with the HDRS-24. Participants who have a 50% or greater decrease in their HDRS-24 score will be considered responders (to treatment). |
Contacts
CONTACTChristine DeLorenzo, Ph.D.
PRINCIPAL_INVESTIGATORRamin Parsey, M.D, Ph.D.
Stony Brook University
Outcome results
None listed